Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AYLANASDAQ:ERYPNASDAQ:FENCNASDAQ:FRLNNASDAQ:GNFT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.50+5.8%$0.48$0.36▼$7.31$7.46M1.9876,300 shs137,700 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AFENCFennec Pharmaceuticals$9.31-2.7%$10.09$6.30▼$11.92$252.30M0.38110,292 shs93,127 shsFRLNFreeline Therapeutics$6.48$6.48$2.11▼$8.74$28.12M0.6612,055 shsN/AGNFTGenfit$3.41-5.0%$3.62$2.89▼$4.75$169.92M1.0815,301 shs1,556 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ERYPERYTECH Pharma0.00%0.00%0.00%-34.04%+236.96%FENCFennec Pharmaceuticals-1.34%-11.63%-13.08%-4.40%+18.59%FRLNFreeline Therapeutics0.00%0.00%0.00%+1.25%+4.10%GNFTGenfit-0.29%-5.74%+0.88%+3.29%-9.22%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.3643 of 5 stars3.50.00.00.02.42.51.9FRLNFreeline Therapeutics0.0452 of 5 stars1.00.00.00.00.00.81.3GNFTGenfit0.8003 of 5 stars3.53.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala PharmaceuticalsN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AFENCFennec Pharmaceuticals3.00Buy$17.3386.18% UpsideFRLNFreeline Therapeutics2.00Hold$4.83-25.41% DownsideGNFTGenfit3.00Buy$11.00222.58% UpsideCurrent Analyst RatingsLatest FRLN, GNFT, FENC, ERYP, and AYLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88FENCFennec Pharmaceuticals$21.25M11.87N/AN/A($0.43) per share-21.65FRLNFreeline TherapeuticsN/AN/AN/AN/A$12.07 per shareN/AGNFTGenfit$41.31M4.11N/AN/A$1.48 per share2.30Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/AERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AFENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.30N/A-75.50%N/A-73.64%5/9/2024 (Estimated)FRLNFreeline Therapeutics-$88.97M-$5.59N/AN/AN/AN/A-150.46%-97.01%N/AGNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)Latest FRLN, GNFT, FENC, ERYP, and AYLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AFRLNFreeline TherapeuticsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28ERYPERYTECH Pharma0.323.653.65FENCFennec PharmaceuticalsN/A3.563.27FRLNFreeline TherapeuticsN/A1.95N/AGNFTGenfit0.922.942.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%ERYPERYTECH Pharma1.09%FENCFennec Pharmaceuticals55.51%FRLNFreeline Therapeutics46.26%GNFTGenfit2.24%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%ERYPERYTECH Pharma1.94%FENCFennec Pharmaceuticals11.25%FRLNFreeline Therapeutics1.90%GNFTGenfit4.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableFENCFennec PharmaceuticalsN/A27.10 million24.06 millionOptionableFRLNFreeline Therapeutics1524.34 million4.26 millionNot OptionableGNFTGenfit15449.83 million47.74 millionNot OptionableFRLN, GNFT, FENC, ERYP, and AYLA HeadlinesSourceHeadlineGENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documentsglobenewswire.com - April 15 at 4:10 PMGENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-Fglobenewswire.com - April 5 at 2:00 PMGenfit's (GNFT) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - April 5 at 8:28 AMGENFIT S.A.: GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - April 5 at 4:56 AMGENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 4 at 4:10 PMEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Tradingmsn.com - April 3 at 12:51 PMGenfit S.A. (NASDAQ:GNFT) Short Interest Updatemarketbeat.com - April 2 at 10:00 AMEuropean Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Tradingmsn.com - March 27 at 1:06 PMGENFIT Announces Revenues and Cash Position as of December 31, 2023globenewswire.com - February 29 at 4:10 PMGENFIT S.A.thestreet.com - February 25 at 1:21 PMInventiva drops after adverse event in Phase 3 trial for NASH drugmsn.com - February 16 at 3:02 PMEuropean Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Tradingmsn.com - February 5 at 12:50 PMEuropean Equities Traded in the US as American Depositary Receipts Trend Lower in Monday Tradingmsn.com - January 29 at 1:31 PMGenfit Stock (NASDAQ:GNFT) Dividends: History, Yield and Datesbenzinga.com - December 21 at 3:56 PMGenfit SA ADR GNFTmorningstar.com - December 20 at 12:33 AMFDA grants priority review of Genfit-Ipsen liver disease drugmsn.com - December 7 at 7:56 AMIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBCmarkets.businessinsider.com - December 7 at 2:56 AMGENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023benzinga.com - November 17 at 9:05 AMGENFIT Reports Third Quarter 2023 Financial Informationfinance.yahoo.com - November 9 at 6:14 PMOil Stocks Buoy European Equities Traded in the US as American Depositary Receipts Thursdaymsn.com - November 9 at 1:13 PMOil Stocks Burden European Equities Traded in the US as American Depositary Receipts Tuesdaymsn.com - November 7 at 12:41 PMGENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technologyfinance.yahoo.com - September 26 at 8:22 PMGENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - September 26 at 3:22 PMGENFIT S.A.: GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - September 22 at 9:33 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.ERYTECH PharmaNASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Freeline TherapeuticsNASDAQ:FRLNFreeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.GenfitNASDAQ:GNFTGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.